

Trust Headquarters  
Russell's Hall Hospital  
Dudley  
West Midlands  
DY1 2HQ

**Ref:** FOI-122024-0001310

**Date:** 13.2.25

**Address / Email:**

Dear

**Request Under Freedom of Information Act 2000**

Thank you for requesting information under the Freedom of Information Act 2000, please see information below.

I am writing to request information on new drugs that have been approved by the National Institute of Health and Care Excellence but have not been made available within your trust. With that in mind I would like to request the following information.

I would like a list of all drugs currently under consideration for use within the trust.

Q1) The following NICE TAs are those that are being considered and are still within the 90-day implementation period post NICE publication (For TA995 and TA769 whereby operational/logistic delivery pathways are being established):

Avapritinib for treating advanced systemic mastocytosis	TA1012
Quizartinib for induction, consolidation and maintenance treatment of newly diagnosed FLT3-ITD-positive acute myeloid leukaemia	TA1013
Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer	TA1014
Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments	TA1015
Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer	TA1017
Palforzia for treating peanut allergy in children and young people <ul style="list-style-type: none"> <li>need to establish a formal treatment pathway</li> </ul>	TA769
Relugolix for treating hormone-sensitive prostate cancer <ul style="list-style-type: none"> <li>the implementation of this has been complex as it has required conversations with the Urology MDT and training of the Urology CNS. We should be able to close this by February 2025</li> </ul>	TA995

Q2) I would like to know within the last year how many drugs have been approved by NICE but rejected for use in your trust. If this is applicable I would like a list of all drugs rejected. - Zero rejected

Q3) I would like to know how much the Trust has spent on drugs for the years 2024, 2023, 2022.

Financial year	2021-22	2022-23	2023-24
Total Drug Spend	£39,239,835.46	£43,106,332.29	£47,955,396.25

Q4) I would like to know how much the Trust has received from NHS England specifically to purchase drugs for 2024, 2023, 2022. -

Financial year	2021-22	2022-23	2023-24
NHSE Drug Income	£16,055,622.54	£19,993,781.36	£22,351,381.17

If you are dissatisfied with our response, you have the right to appeal in line with guidance from the Information Commissioner. In the first instance you may contact the Information Governance Manager of the Trust.

Information Governance Manager  
Trust Headquarters  
Russell’s Hall Hospital  
Dudley  
West Midlands  
DY1 2HQ  
Email: [dgft.dpo@nhs.net](mailto:dgft.dpo@nhs.net)

Should you disagree with the contents of our response to your appeal, you have the right to appeal to the Information Commissioners Office at.

Information Commissioners Office  
Wycliffe House  
Water Lane  
Wilmslow  
Cheshire  
SK9 5AF  
Tel: 0303 123 1113  
[www.ico.org.uk](http://www.ico.org.uk)

If you require further clarification, please do not hesitate to contact us.

Yours sincerely

**Freedom of Information Team**  
**The Dudley Group NHS Foundation Trust**